Form 8-K - Current report:
SEC Accession No. 0001193125-25-120910
Filing Date
2025-05-15
Accepted
2025-05-15 17:00:10
Documents
13
Period of Report
2025-05-13
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d938755d8k.htm   iXBRL 8-K 26169
  Complete submission text file 0001193125-25-120910.txt   152509

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA howl-20250513.xsd EX-101.SCH 2860
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE howl-20250513_lab.xml EX-101.LAB 18738
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE howl-20250513_pre.xml EX-101.PRE 11714
15 EXTRACTED XBRL INSTANCE DOCUMENT d938755d8k_htm.xml XML 3769
Mailing Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472
Business Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472 617-952-0555
Werewolf Therapeutics, Inc. (Filer) CIK: 0001785530 (see all company filings)

EIN.: 823523180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40366 | Film No.: 25955075
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)